A5070113542- Monoclonal and Polyclonal Antibodies Research
- HER2/EGFR in Cancer Research
- Head and Neck Cancer Studies
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Gastric Cancer Management and Outcomes
- Lymphoma Diagnosis and Treatment
- Esophageal Cancer Research and Treatment
- Cancer Immunotherapy and Biomarkers
- Advanced Biosensing Techniques and Applications
- Advanced Breast Cancer Therapies
- Brain Metastases and Treatment
- Chronic Lymphocytic Leukemia Research
- Colorectal Cancer Treatments and Studies
- Radiomics and Machine Learning in Medical Imaging
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Thyroid Cancer Diagnosis and Treatment
- Virus-based gene therapy research
- Angiogenesis and VEGF in Cancer
- Cancer Genomics and Diagnostics
- Peptidase Inhibition and Analysis
- Cancer Research and Treatments
- CNS Lymphoma Diagnosis and Treatment
- T-cell and Retrovirus Studies
Shanghai Medical College of Fudan University
2013-2025
Fudan University Shanghai Cancer Center
2016-2025
First Affiliated Hospital of Anhui Medical University
2021-2025
Anhui Medical University
2017-2025
Ministry of Education of the People's Republic of China
2021-2024
Shanghai University of Electric Power
2024
Chinese Academy of Medical Sciences & Peking Union Medical College
2023
Xuzhou Medical College
2022
Anhui Provincial Hospital
2022
Second People’s Hospital of Huai’an
2022
Patients with metastatic gastric cancer (mGC) who do not respond to or experience progression second-line chemotherapy have no treatment options that clearly confer a survival benefit. This trial investigated the safety and efficacy of apatinib, an inhibitor vascular endothelial growth factor receptor, as option for heavily pretreated patients mGC.Patients experienced failure at least two chemotherapeutic regimens were randomly assigned receive placebo (group A), apatinib 850 mg once daily...
Abstract The tumor ecosystem of papillary thyroid carcinoma (PTC) is poorly characterized. Using single-cell RNA sequencing, we profile transcriptomes 158,577 cells from 11 patients’ paratumors, localized/advanced tumors, initially-treated/recurrent lymph nodes and radioactive iodine (RAI)-refractory distant metastases, covering comprehensive clinical courses PTC. Our data identifies a “cancer-primed” premalignant thyrocyte population with normal morphology but altered transcriptomes. Along...
ARX788 is a novel antibody-drug conjugate (ADC) comprised of an anti-HER2 monoclonal antibody and potent tubulin inhibitor payload AS269 that site-specifically conjugated to the via non-natural amino acid incorporated into antibody. Herein, we present results phase I study safety, pharmacokinetics, antitumor activity in HER2-positive metastatic breast cancer (MBC) patients.Patients with MBC received at doses 0.33, 0.66, 0.88, 1.1, 1.3, or 1.5 mg/kg Q3W, 1.3 Q4W. The dose-limiting toxicity...
Background The programmed death 1 inhibitor toripalimab plus the angio-immuno kinase surufatinib revealed a tolerable safety profile and preliminary efficacy in patients with advanced solid tumours phase I study. Patients methods This was an open-label, single-arm, multi-cohort II study China. neuroendocrine (NETs) or carcinomas (NECs) mixed non-neuroendocrine neoplasms (MiNENs) who had failed were intolerable of standard treatment given (250 mg orally, once daily) (240 intravenously, every...
Abstract Backgrounds Immune checkpoint blockade (ICB) is widely considered to exert long-term treatment benefits by activating antitumor immunity. However, many cancer patients show poor clinical responses ICB due in part the lack of an immunogenic niche. Focal adhesion kinase (FAK) frequently amplified and acts as immune modulator across types. evidence illustrates that targeting FAK most effective combination therapy rather than monotherapy. Methods Here, we used drug screening, vitro vivo...
Both anaplastic thyroid cancer (ATC) and papillary (PTC) originate from follicular epithelial cells, but ATC has a significantly worse prognosis shows resistance to conventional therapies. However, clinical trials found that immunotherapy works better in than late-stage PTC. Here, we utilized single-cell RNA sequencing (scRNA-seq) generate atlas of cancer. Differences PTC tumor microenvironment (TME) components (including malignant stromal immune cells) leading the polarized prognoses were...
KN026 is a novel bispecific antibody that simultaneously binds to two distinct HER2 epitopes. This first-in-human phase I study evaluated the safety/tolerability, pharmacokinetics, preliminary efficacy, and potential predictive biomarker activity of administered as monotherapy patients with HER2-positive metastatic breast cancer (MBC).Female MBC who had progressed on prior anti therapies received intravenous at 5 mg/kg (once weekly), 10 20 every 2 weeks), or 30 3 weeks). Dose escalation was...
Combining the programmed death-1 inhibitor toripalimab and angio-immuno kinase surufatinib showed preliminary antitumor activity in patients with advanced solid tumors a phase I study. Here, we report efficacy safety of this combination regimen treatment-naive or metastatic non-small-cell lung cancer (NSCLC) death-ligand 1 (PD-L1) tumor proportion score (TPS) 1% greater (PD-L1-positive) previously treated small-cell (SCLC). This open-label, single-arm II study included PD-L1-positive NSCLC...
Targeting human epidermal growth factor receptor 2 (HER2) therapy is currently considered as the standard treatment for HER2-positive (HER2+) advanced gastric cancer. However, seen in recent clinical trials, most of HER2+ cancer are actually unresponsive to HER2-targeted agents, including lapatinib. The aim this study identify responsible tyrosine kinases (RTK) potentially conferring lapatinib unresponsiveness and elucidate molecular mechanism underlying RTKs-induced resistance.A functional...
Abstract Background HL-085 is a selective, orally administered MEK1/2 inhibitor. We aimed to evaluate the safety and efficacy of in patients with advanced melanoma harboring NRAS mutations. Methods This was multicenter phase 1 study. twice daily standard 3 + dose-escalation design (10 dose cohorts; 0.5–18 mg daily), followed by expansion at recommended II (RP2D). The primary endpoints included tolerability, dose-limiting toxicity (DLT), maximum tolerated (MTD) RP2D. Results Between September...
The aim of this study was to assess the efficacy, toxicities, and potential role larynx preservation induction chemotherapy combined with programmed cell death protein 1 (PD-1) inhibitor in locally advanced laryngeal hypopharyngeal cancer.
Abstract Background: Reactivation of hepatitis B virus (HBV) is less common in lymphoma patients with prior resolved HBV infection [characterized by surface antigen (HBsAg)‐negative/hepatitis core antibody (HBcAb)‐positive status] compared chronic (HBsAg positive) when receiving chemotherapy alone. The use rituximab regimen might increase the risk reactivation infection. However, incidence uncertain, and prophylactic antiviral treatment for this group during rituximab‐containing...
In the current study, we showed that combination of mammalian target rapamycin (mTOR) inhibitor RAD001 (everolimus) and Akt MK-2206 exerted synergistic cytotoxic effects against low-phosphatase tensin homolog (PTEN) gastric cancer cells (HGC-27 SNU-601 lines). HGC-27 cells, synergistically induced G1/S cell cycle arrest, growth inhibition, death but not apoptosis. light chain 3B (LC3B) beclin-1 expression, two important autophagy indicators. Meanwhile, 3-methyladenine (3-MA) chloroquine...
Antagonizing the androgen-receptor (AR) pathway is an effective treatment strategy for patients with metastatic castration-resistant prostate cancer (CRPC). Here, we report results of a first-in-human phase 1/2 study which assessed safety, pharmacokinetics, and activity SHR3680 (a novel AR antagonist) in CRPC.This enrolled progressive CRPC who had not been previously treated AR-targeted agents. In 1 dose-escalation portion, received oral at starting daily dose 40 mg, was subsequently...
To evaluate the feasibility of early metabolic change assessed by PET in predicting clinical response to chemotherapy and investigate its prognostic value patients with advanced gastric cancer.A total 64 cancer were prospectively enrolled examined (18)F-fluorodeoxyglucose (FDG) (18)F-fluoro-3'-deoxy-3'-L-fluorothymidine (FLT) at baseline 14 days after treatment initiation. findings analyzed for correlation best patients, disease control status, survival identifying threshold percentage ROC...
1038 Background: ARX788 is a site-specific, homogeneous, and highly stable ADC. The payload AS269 conjugated to the synthetic amino acids para-acetylphenylalanine (pAF) in humanized anti-HER2 mAb. demonstrated promising activity HER2-positive, HER2-low, T-DM1 resistant tumors preclinical studies. Here we present phase 1 clinical data evaluating safety, antitumor activity, PK of advanced solid tumors. Methods: standard 3+3 design (0.33 - 1.5 mg/kg; Q3W or Q4W) used determine MTD and/or RP2D...
Chidamide is an oral histone deacetylase subtype-selective inhibitor approved for relapsed or refractory peripheral T-cell lymphoma (PTCL). This phase 1b study evaluated the safety, pharmacokinetics, and preliminary efficacy of chidamide in combination with cyclophosphamide, doxorubicin, vincristine prednisone (CHOP) treatment-naïve PTCL patients.This was open-label, multicenter trial composed dose escalation expansion. Patients received CHOP six 21-d cycles on d 1, 4, 8 11 each cycle. Four...
e18062 Background: Salivary gland cancers (SGCs) exhibit high heterogeneity in molecular and genomic characteristics, which provides a basis for targeted therapies of SGCs. Until recently, the gene targets precision therapy drugs mainly included HER2, NTRK, TROP2, androgen-receptor (AR), etc. Herein, we report preliminary result single-center, open-label, phase II umbrella clinical trial evaluating efficacy safety subtype-guided advanced salivary cancer (NCT05924256). Methods: Patients (pts)...